Charles River, AstraZeneca partner to accelerate drug development
Under the agreement that extends for three years, Charles River will provide DMPK studies that support drug candidate selection or regulatory submission and services that aid in testing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.